TechBio® is
the convergence
of tech and bio
engineering applied
to life sciences
an iterative
process
a platform
approach
AI and data-enabled
discovery
cures instead
of treatments
personalized
medicine
tech-enabled
healthcare at scale
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
.svg)
Seven tailwinds driving TechBio®
.svg)
.svg)
The significant reduction in sequencing time and costs for omics (genomic, transcriptomic, metabolomic, proteomic, etc) has enabled widespread usage of this sequenced data to create an “open source” approach to science and R&D.
The digitization of biology allows us to convert biological data and information into digital information that can be stored, analyzed and processed by computers. Software has enabled us to communicate this language of biology to make this data more accessible to researchers worldwide, accelerate drug development, improve clinical trial matching, personalize medicines and more.
Increasing business development in life sciences
Breakdown by R&D source of late-stage pipeline
Increasing business development in life sciences
Innovation in the modern day era comes from corporations acquiring companies where innovation is happening. This trend has enabled greater opportunities for TechBio companies to develop innovative platforms that license out assets to pharma, tech giants, payers, retail pharmacies and more.
Expanded data creation and advanced computing
generation
Expanded data creation and advanced computing
Computation and prediction have outpaced experimentation. Consider that in the world of protein sequence prediction, AlphaFold2 expanded their database 200x from ~1M to 200M+ structures compared with the <200K structures that have been experimentally resolved. TechBio has the potential to dramatically increase our understanding of biology and apply it in new ways.
Better knowledge of biological processes
Better knowledge of biological processes
Our increased understanding of biology will fuel a future of in-vivo biology, where drugs can be personalized to an individual. From gene editing to discovering novel targets, we now have novel biology that can be the catalyst for a whole new applied world.
Skyrocketing drug development costs
Estimated median expense on new FDA approved drugs (2009–2018)
Skyrocketing drug development costs
On average, it costs about $1.3 billion to bring a new drug to market; in the field of oncology and immunology drugs, this average cost is more than double, or about $2.8 billion. TechBio aims to reduce these skyrocketing costs by applying AI and engineering across the drug development continuum from novel target identification to preclinical disease modeling, clinical trial patient recruitment and beyond.
Annual storage in petabytes per year (2025 projection)
Cost-effective data storage will enable us to utilize the growing amount of biological data being generated and shared. Genomics data is expected to require up to 40,000 petabytes of storage each year by 2025, compared to X (fka Twitter) which is estimated to require 17 petabytes a year or all the data collected on astronomy (1,000 petabytes a year).
The convergence in action
Excision is focused on developing advanced gene editing therapeutics
Excision is curing viral infections by harnessing the power of CRISPR/Cas9 gene editing technology and multiple computer guided RNA targets to remove large segments of viral DNA from the genome returning the genome to normal and eliminating the possibility of viral escape
Excision's guide RNA platform and technology is applicable to multiple viral diseases that carry a large disease burden for their patients, such as Herpes Simplex Virus (HSV), Hepatitis B and PML/JCV.
“I am optimistic that Excision’s technology and approach using CRISPR could potentially cure infectious diseases and bring much needed therapies to those in need around the world”
